From the Blogs: FDA Approves First PI-Based Single-Tablet Treatment for HIV — How Will It Be Used?

In HIV and ID Observations, Dr. Paul Sax takes a look at how the first protease inhibitor–based single-tablet treatment for HIV will it be used.

The FDA recently approved a new drug for HIV — a single-tablet treatment containing darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. DCF-TAF is the first full treatment regimen in a single pill with a protease inhibitor. In the latest HIV and ID Observations blog post, Dr. Paul Sax discusses the challenges that could limit widespread adoption of this new tablet.

Want to see more from NEJM Journal Watch? Register here.

From the Blogs: FDA Approves First PI-Based Single-Tablet Treatment for HIV — How Will It Be Used?

Topics